Sachin Jain
Stock Analyst at Bank of America Securities
(3.04)
# 2,694
Out of 4,712 analysts
229
Total ratings
53.8%
Success rate
2.5%
Average return
Main Sectors:
Stocks Rated by Sachin Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,500p | 11,650p | +41.63% | 86 | Sep 8, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 140.00 → CHF 150.00 | CHF 111.66 | +34.34% | 29 | Sep 7, 2026 | |
| NVS Novartis AG | Reiterated: Buy | $173 → $185 | $137.48 | +34.82% | 6 | Sep 7, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €92.00 | €74.24 | +23.92% | 24 | Sep 4, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,350p | 1,804p | +30.30% | 16 | Sep 4, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €30.00 → €35.00 | €49.26 | -28.95% | 9 | Dec 2, 2025 | |
| BME: GRF Grifols, S.A. | Reiterated: Buy | €10.60 | €9.96 | +6.47% | 1 | Nov 25, 2025 | |
| GSK GSK plc | Reiterated: Sell | $48 → $23 | $48.63 | -52.77% | 4 | Oct 29, 2025 | |
| NVO Novo Nordisk | Reiterated: Hold | $141 → $58 | $44.56 | +30.75% | 37 | Oct 9, 2025 | |
| SWX: ROP Roche Holding AG | Upgraded: Buy | CHF 275.00 → CHF 340.00 | CHF 347.70 | n/a | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €110.00 → €205.00 | €132.70 | n/a | 3 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $49 | $33.04 | n/a | 4 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $24 | $28.49 | n/a | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $195 | $135.61 | n/a | 1 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $27.78 | n/a | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $175.80 | n/a | 1 | May 2, 2016 |
AstraZeneca PLC
Sep 8, 2026
Reiterated: Buy
Price Target: 16,500p
Current: 11,650p
Upside: +41.63%
Novartis AG
Sep 7, 2026
Reiterated: Buy
Price Target: CHF 140.00 → CHF 150.00
Current: CHF 111.66
Upside: +34.34%
Novartis AG
Sep 7, 2026
Reiterated: Buy
Price Target: $173 → $185
Current: $137.48
Upside: +34.82%
Sanofi
Sep 4, 2026
Reiterated: Hold
Price Target: €92.00
Current: €74.24
Upside: +23.92%
GSK plc
Sep 4, 2026
Reiterated: Hold
Price Target: 2,350p
Current: 1,804p
Upside: +30.30%
Bayer Aktiengesellschaft
Dec 2, 2025
Reiterated: Buy
Price Target: €30.00 → €35.00
Current: €49.26
Upside: -28.95%
Grifols, S.A.
Nov 25, 2025
Reiterated: Buy
Price Target: €10.60
Current: €9.96
Upside: +6.47%
GSK plc
Oct 29, 2025
Reiterated: Sell
Price Target: $48 → $23
Current: $48.63
Upside: -52.77%
Novo Nordisk
Oct 9, 2025
Reiterated: Hold
Price Target: $141 → $58
Current: $44.56
Upside: +30.75%
Roche Holding AG
Sep 13, 2024
Upgraded: Buy
Price Target: CHF 275.00 → CHF 340.00
Current: CHF 347.70
Upside: n/a
Jun 12, 2023
Reiterated: Buy
Price Target: €110.00 → €205.00
Current: €132.70
Upside: n/a
May 11, 2023
Reiterated: Buy
Price Target: $48 → $49
Current: $33.04
Upside: n/a
Feb 2, 2023
Reiterated: Hold
Price Target: $24
Current: $28.49
Upside: n/a
Jan 17, 2023
Reiterated: Hold
Price Target: $195
Current: $135.61
Upside: n/a
Nov 1, 2022
Reiterated: Buy
Price Target: $60
Current: $27.78
Upside: n/a
May 2, 2016
Reiterated: Buy
Price Target: n/a
Current: $175.80
Upside: n/a